Skip to content
EVHEvolent Health, Inc.

Earnings

When Evolent Health, Inc. reports, what it reported each quarter, and how the stock took the results.

51 quarters. Mar 31, 2014 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 23, before the open

Tue, Feb 23, 2027in 97 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 3

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$468.72M
Revenue, change from a year earlier: Q3 2026 +51.3%, Q2 2026 +46.9%, Q1 2026 +2.6%, Q4 2025 −27.5%
Net income
-$429.13M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
-$3.84
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m

Quarter by quarter

Q3 2026$725.37M+51.3% vs Q3 2025

Latest results

  1. Q3 2026Nov 5, 2026, before the openThe release5.5%by the close of Nov 5
    Revenue
    $725.37M
    +51.3%
    Net income
    -$23.57M
    N/M
    EPS
    -$0.21
    N/M
    Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range to $2.6 billion to $2.7 billion and raising its Adjusted EBITDA range to $130.0 million to $135.0 million.
  2. Q2 2026Aug 6, 2026, before the openThe release+17.1%by the close of Aug 6
    Revenue
    $652.52M
    +46.9%
    Net income
    -$28.36M
    N/M
    EPS
    -$0.25
    N/M
  3. Q1 2026May 7, 2026, before the openThe release+11.6%by the close of May 7
    Revenue
    $496.25M
    +2.6%
    Net income
    -$26.63M
    N/M
    EPS
    -$0.24
    N/M
  4. Q4 2025Feb 24, 2026, after the closeThe release+23.6%by the close of Feb 25
    Revenue
    $468.72M
    −27.5%
    Net income
    -$429.13M
    N/M
    EPS
    -$3.84
    N/M

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · pre-marketNov 5, 202636 d10-Q$725.37M+51.3%-$0.215.5%
Q2 2026Jun 30, 2026Aug 6, 2026 · pre-marketAug 6, 202637 d10-Q$652.52M+46.9%-$0.25+17.1%
Q1 2026Mar 31, 2026May 7, 2026 · pre-marketMay 7, 202637 d10-Q$496.25M+2.6%-$0.24+11.6%
FY 2025
Q4 2025Dec 31, 2025Feb 24, 2026 · after-hoursFeb 25, 202656 d10-K$468.72M−27.5%-$3.84+23.6%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 7, 202538 d10-Q$479.53M−22.8%-$0.2417.6%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 11, 202542 d10-Q$444.33M−31.3%-$0.447.0%
Q1 2025Mar 31, 2025May 8, 2025 · after-hoursMay 9, 202539 d10-Q$483.65M−24.4%-$0.6316.0%
FY 2024
Q4 2024Dec 31, 2024Feb 20, 2025 · after-hoursFeb 21, 202552 d10-K$646.54M+16.3%-$0.272.8%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 8, 202439 d10-Q$621.40M+21.6%-$0.2745.8%
Q2 2024Jun 30, 2024Aug 8, 2024 · after-hoursAug 9, 202440 d10-Q$647.15M+37.9%-$0.06+25.5%
Q1 2024Mar 31, 2024May 9, 2024 · after-hoursMay 10, 202440 d10-Q$639.65M+49.6%-$0.22—
Earlier years, FY 2014 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026000100
10-QAug 6, 2026000086
10-QMay 7, 2026000033
10-KFeb 25, 2026000015
10-QNov 7, 2025000133
10-QAug 11, 2025000116
10-QMay 9, 2025000066
10-KFeb 21, 2025000020
10-QNov 8, 2024000114
10-QAug 9, 2024000090

Provenance

ProvenanceData status and checks

Evolent Health, Inc. · CIK 1628908 · Engraved from SEC EDGAR